Detalhe da pesquisa
1.
First German-speaking harm reduction conference in Vienna.
Harm Reduct J
; 21(1): 12, 2024 Jan 16.
Artigo
em Inglês
| MEDLINE | ID: mdl-38229089
2.
Towards an International Consensus on the Prevention, Treatment, and Management of High-Risk Substance Use and Overdose among Youth.
Medicina (Kaunas)
; 58(4)2022 Apr 13.
Artigo
em Inglês
| MEDLINE | ID: mdl-35454376
3.
Retention in the Austrian opioid agonist treatment system: a national prospective cohort study.
Harm Reduct J
; 18(1): 25, 2021 02 24.
Artigo
em Inglês
| MEDLINE | ID: mdl-33627159
4.
CHIME - A tailored HCV microelimination project in Viennese people who inject drugs at drug centralized substitution centers.
J Virus Erad
; 9(3): 100338, 2023 Sep.
Artigo
em Inglês
| MEDLINE | ID: mdl-37663576
5.
Direct Observed Therapy of Chronic Hepatitis C With Interferon-Free All-Oral Regimens at a Low-Threshold Drug Treatment Facility-a New Concept for Treatment of Patients With Borderline Compliance Receiving Opioid Substitution Therapy.
Am J Gastroenterol
; 111(6): 903-5, 2016 06.
Artigo
em Inglês
| MEDLINE | ID: mdl-27249993
6.
Directly observed therapy at opioid substitution facilities using sofosbuvir/velpatasvir results in excellent SVR12 rates in PWIDs at high risk for non-adherence to DAA therapy.
PLoS One
; 16(6): e0252274, 2021.
Artigo
em Inglês
| MEDLINE | ID: mdl-34086708
7.
Directly observed therapy for HCV with glecaprevir/pibrentasvir alongside opioid substitution in people who inject drugs-First real world data from Austria.
PLoS One
; 15(3): e0229239, 2020.
Artigo
em Inglês
| MEDLINE | ID: mdl-32155165
8.
Efficacy of ledipasvir/sofosbuvir plus ribavirin for 12 weeks in patients with chronic hepatitis C genotype 3 and compensated liver disease.
Eur J Gastroenterol Hepatol
; 30(3): 291-295, 2018 Mar.
Artigo
em Inglês
| MEDLINE | ID: mdl-29120906